Fara Brasó-Maristany
Research group
- Translational genomics and targeted therapies in solid tumours Post-doctoral researcher (R2A)
About me
My main researched is focused on the identification of biomarkers of response and mechanisms of resistance to targeted therapies in breast cancer.
Featured publications
-
Gene expression profiles of breast cancer metastasis according to organ site
Authors:Reference: Molecular Oncology 2022. -
Case Report: A Case Study Documenting the Activity of Atezolizumab in a PD-L1-Negative Triple-Negative Breast Cancer
Authors:Reference: Frontiers In Oncology 2021. -
Oestrogen receptor activity in hormone-dependent breast cancer during chemotherapy: ER activity in pre-menopausal HR+ breast cancer during CT
Authors:Reference: Ebiomedicine 2021. -
Correlative Biomarker Analysis of Intrinsic Subtypes and Efficacy Across the MONALEESA Phase III Studies
Authors:Reference: Journal Of Clinical Oncology 2021. -
Circulating tumor DNA dynamics in advanced breast cancer treated with CDK4/6 inhibition and endocrine therapy
Authors:Reference: Npj Breast Cancer 2021. -
A prognostic model based on PAM50 and clinical variables (PAM50MET) for metastatic hormone-receptor-positive HER2-negative breast cancer
Authors:Reference: Clinical Cancer Research 2020. -
ERBB2 mRNA Expression and Response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer
Authors:Reference: Cancers 2020. -
Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade
Authors:Reference: Nature Communications 2020. -
HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade
Authors:Reference: Journal Of The National Cancer Institute 2020. -
PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer
Authors:Reference: Nature Medicine 2016.
Featured Projects
-
Identification and validation of therapeutic targets to overcome resistance to CDK4/6 inhibitors in metastatic hormone receptor-positive HER2-negative breast cancer.
Principal investigator: Fara Brasó MaristanyFunder: Fundación Científica Asociación Española Contra el Cáncer (AECC).Code: INVES21943BRASDuration: 01/12/2021 - 30/11/2024 -
Estudio de los mecanismos de sensibilidad y resistencia al doble bloqueo HER2 y a las combinaciones con enzalutamida o palbociclib en modelos preclínicos de cáncer de mama HER2-positivo
Principal investigator: Aleix PratFunder: Asociación Española Contra el Cáncer (AECC) ; Fundación Científica Asociación Española Contra el Cáncer (AECC).Code: Ayuda Postdoctoral AECC 2017Duration: 01/11/2017 - 31/10/2021